CRNX - Company ID 0001658247
The table below shows Crinetics Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $10.73M | $143.00K | $1.03M | $361.00K | $0.00 | $399.00K |
| Cost of revenue | $200.00K | - | - | $0.00 | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $100.08M | $90.46M | $80.30M | $76.24M | $61.91M | $58.34M |
Crinetics Pharmaceuticals, Inc. reported annual revenue of $7.70M for fiscal year 2025. That is up 640.7% from $1.04M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $589.00K (FY 2016) to $7.70M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $50.83M |
| $52.27M |
| $49.84M |
| $35.53M |
| $25.89M |
| $24.84M |
| Operating income | -$140.38M | -$142.59M | -$129.11M | -$111.41M | -$87.80M | -$82.78M |
| Income tax | - | - | - | - | - | - |
| Net income | -$127.84M | -$130.09M | -$115.64M | -$96.77M | -$76.83M | -$74.06M |
| EPS (diluted) | -$1.23 | -$1.38 | -$1.23 | -$1.04 | -$0.96 | -$0.94 |